The Psychedelic Executive Order: A New National Health Priority

WASHINGTON — In what may be the most radical healthcare shift of the decade, the White House has issued an Executive Order to fast-track the approval of psychedelic-assisted therapies. The order specifically targets compounds like ibogaine and psilocybin, directing federal agencies to move from clinical trials to public availability in as little as two months for "high-priority" mental health cases.

The administration is framing the move as a way to bolster "national resilience" and address the veteran suicide crisis. However, the speed of the rollout has raised alarms among some FDA regulators who worry that the two-month timeline is insufficient to ensure long-term safety.

Despite the medical concerns, the White House is leaning into the optics of a "medical revolution." By bypassing traditional bureaucratic hurdles, the President is positioning himself as a disruptor of the "Big Pharma" status quo, a move that is already attracting significant interest from venture capitalists and tech-health startups looking to capitalize on the new "legal" frontier.